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This study investigated the relation between positive thyroid transcription factor 1 (TTF1) staining and survival of patients affected by
primary adenocarcinoma (ADC) of the lung. Pathological tissue from consecutive ADC patients was collected from 2002 to 2004.
The anti-TTF1 antibody (8G7G3/1, dilution of 1/200) was used. Thyroid transcription factor 1 staining was assessed for each tumour
as positive or negative. Probability of survival was estimated by Kaplan–Meier and difference tested by log-rank test. A Cox’s
regression multivariate analysis was carried out. In all, 106 patients were studied (66% male, 69% PS0–1, 83% with stage III or IV).
Tumours expressed positive TTF1 staining in 66% of cases. Multivariate analysis demonstrated an independent lower risk of death for
patients whose tumour expresses positive TTF1 staining (HR¼0.51, 95% CI 0.30–0.85; P¼0.01) and higher grade of differentiation
(HR¼0.40, 95% CI 0.24–0.68; P¼0.001). In conclusion, positive TTF1 staining strongly and independently correlates with survival of
patients with primary ADC of the lung.
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Primary adenocarcinoma (ADC) of the lung has risen in incidence,
now reaching approximately 50% of non-small-cell lung cancer
(NSCLC). However, identification of primary ADC is sometimes
difficult but has been enhanced by the use of the thyroid
transcription factor 1 (TTF1) immunostaining. Indeed, positive
TTF1 staining has been shown for 75–80% of primary ADC while
negative for virtually all squamous carcinoma (SCC) of the lung as
well as for extrapulmonary but thyroid tumours (Stenhouse et al,
2004).
The prognostic value for a positive TTF1 staining has been
associated with contradictory results for NSCLC patients. A study
on 222 stage I NSCLC patients demonstrated no survival difference
associated with TTF1 immunoreactivity (Pelosi et al, 2001), while
another study correlated a positive TTF1 staining of resected NSCLC
with a poor survival (Puglisi et al, 1999). On the other hand, four
studies on early stages of NSCLC associated a positive TTF1 staining
with a longer survival (Haque et al, 2002; Myong, 2003; Tan et al,
2003; Saad et al, 2004). However, all these studies were interested in
surgical NSCLC patients and all but one (Saad et al, 2004) included
both ADC and non-ADC histological types of NSCLC.
The aim of the present study was to investigate the relation of a
positive TTF1 staining with survival of patients (1) affected
exclusively by a primary ADC of the lung and (2) mainly
presenting with locally advanced or metastatic stage of the disease.
PATIENTS AND METHODS
All consecutive patients diagnosed with ADC from January 2002 to
May 2004 at our department were included in the study.
Histological subclassification was carried out according to the
World Health Organization classification (Travis et al, 1999).
Performance status (PS) was estimated using the Eastern
Cooperative Oncology Group (ECOG) scale. Clinical examination
and computed tomographic scan of the chest, abdomen and brain
were carried out systematically.
Pathological tissue was obtained from each patient before
treatment. The pathological tissue was obtained either from the
primary tumour in the majority of cases, or from mediastinal
lymph nodes (n¼10) or distant metastases (n¼5). The patholo-
gical tissue was extracted from surgical specimens when available.
Tumours have been classified into poorly, moderately and well-
differentiated tumours (Travis et al, 1999). Immunohistochemical
staining was carried out on formalin-fixed, paraffin-embedded
tissue samples, using a standard streptavidin–biotin-based
method. The anti-TTF1 antibody (8G7G3/1, mouse monoclonal
antibody; Dako, Ely, Cambridgeshire, UK) was used at a dilution of
1/200. Scoring was carried out independently by two pathologists
(AL and BC). For each tumour, neoplastic cells were assessed as
positive or negative for TTF1 staining (Figure 1). Sole nuclear
staining was considered as a positive result. Any positive nuclear
staining was sufficient to deem a tumour as positive for TTF1
staining. In each case, normal alveolar walls served as positive
internal control. All patients consented to treatment and
were treated with thoracic surgery, radiation therapy and/or
Revised 21 April 2005; accepted 20 June 2005; published online 26 July
2005
*Correspondence: Dr F Barle ´si; E-mail: fabrice.barlesi@mail.ap-hm.fr
British Journal of Cancer (2005) 93, 450–452
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
schemotherapy, in accordance with national and international
guidelines (Depierre et al, 2003) after a multidisciplinary assess-
ment of their disease.
Survival data were updated in March 2005. One patient was
lost to follow-up. Probability of survival was estimated using the
Kaplan–Meier method. Differences between survival were tested
by means of log-rank test. A multivariate regression analysis was
carried out with Cox’s regression using the forward maximum
likelihood method. All variables with a P-value less than 0.20 at the
time of univariate analysis were entered into the model. A P-value
less than 0.05 was considered as significant.
RESULTS
In all, 106 patients were included into the study (Table 1).
Tumours expressing positive TTF1 staining were associated
neither with demographics (i.e. gender and age) nor with disease
characteristics (i.e. PS, TNM stage or presence of metastasis). 1.0
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Figure 1 Survival curves of patients whose tumours showed positive and
negative TTF1 staining.
Figure 2 Acinar ADC (haematoxylin and eosin,  100) (A) showing positive nuclear TTF1 staining (B), and acinar ADC (haematoxylin and eosin,
 100) (C) showing negative TTF1 staining (D).
Table 1 Main clinical and pathological characteristics of the 106 patients
n (%)
Age, o70/X70 years 82 (77)/24 (23)
Gender, women/men 36 (34)/70 (66)
PS, 0–1/X2 (ECOG) 73 (69)/33 (31)
Stage
a
Early stage (I and II) 18 (17)
Locally advanced stage (IIIA and IIIB) 35 (33)
Distant metastasis (IV) 53 (50)
Histological differentiation
Poorly differentiated 38 (36)
Moderately differentiated 47 (44)
Well differentiated 21 (20)
TTF1 staining (positive/negative) 70 (66)/36 (33)
aUICC Classification. PS¼performance status; TTF1¼thyroid transcription factor 1.
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tumours differentiation, as poorly, moderately and well-differ-
entiated tumours expressed a positive TTF1 staining in 21 (30% of
the tumours showing positive TTF1 staining), 35 (50%) and 14
(20%) cases, respectively (P¼0.177).
At the time of analysis, 75 patients were deceased. In univariate
analysis, tumours differentiation and TTF1 staining significantly
correlated with survival. Tumours stage as well as PS also
influenced survival, without reaching statistical significance
(Table 2). Multivariate analysis demonstrated a statistically
significant and independent lower risk of death for patients whose
tumour expresses a positive TTF1 staining (HR¼0.40, 95% CI
0.25–0.65; Po0.0001) (Figure 2), and a statistically significant and
independent lower risk of death for patients whose tumour
expresses higher grade of differentiation (HR¼0.64, 95% CI 0.46–
0.91; P¼0.01).
DISCUSSION
This study highlights the decreased risk of death for patients with
primary ADC of the lung showing a positive TTF1 staining
(HR¼0.40, 95% CI 0.25–0.65; Po0.0001).
Previous studies suggested either a favourable or an unfavour-
able prognosis for patients with tumour showing a positive TTF1
staining. However, all these studies but one (Saad et al, 2004)
included NSCLC patients with a mixture of histological types.
However, the prevalence of a positive TTF1 staining varies
throughout histological types, from 80% for ADC to less than
10% for SCC. This heterogeneity probably explains the conflicting
results previously reported. In addition, available data on the
prognosis associated with TTF1 staining considered exclusively
surgically treated NSCLC patients. Thus, the results reported
herein extend the favourable prognosis related to a positive TTF1
staining to patients with advanced stage of primary ADC of the
lung.
The reasons why TTF1 is related to prognosis of patients with
primary ADC of the lung are unclear. A positive TTF1 staining has
been inversely related to the proliferative activity evaluated
through Ki-67 expression, usually considered as a marker of poor
prognosis in NSCLC (Pelosi et al, 2001; Myong, 2003). On the other
hand, a correlation between positive TTF1 staining and various
molecular markers expression such as p53 or HER2/neu involved
in lung carcinogenesis has been suggested (Haque et al, 2002;
Yatabe et al, 2002; Myong, 2003). Thus, further biological
investigations are needed.
Finally, a significant relationship between positive TTF1 staining
and female gender or nonsmoker status has been suggested
(Yatabe et al, 2002). Thus, a correlation with epidermal growth
factor receptor tyrosine kinase inhibitors activity should be
prospectively investigated. In fact, a TTF1 influence on patients’
survival through difference in treatment sensibility might be
hypothesised.
In conclusion, positive TTF1 staining strongly and indepen-
dently correlates with survival of patients with ADC of the lung by
a way to be identified.
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Table 2 Major results of univariate analysis
Median survival (months) P
PS
0o r1 1 2 N S
X25
Stage
I and II 10 NS
IIIA and IIIB 12
IV 7
TTF1 staining
Positive 14 o0.00001
Negative 5
Differentiation
Poorly 5 0.004
Moderately 13
Well 12
PS¼performance status (ECOG); TTF1¼thyroid transcription factor 1; NS¼non-
significant.
TTF1 and survival of patients with adenocarcinoma of the lung
F Barle ´si et al
452
British Journal of Cancer (2005) 93(4), 450–452 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s